Dandelion Health, the clinical intelligence platform for life sciences, has raised a $14 million Series A funding round led by Healthier Capital, with participation from Colle Capital and existing investors Primary Venture Partners, Moxxie Ventures, and Convergent Ventures. The investment will accelerate Dandelion’s growth in pharmaceutical drug development, deepen its data infrastructure, expand pharma partnerships, and bring its platform to more research and commercial teams across the industry.
Built on a network spanning 73 hospitals and more than 15 million patients, Dandelion’s platform combines structured data, including electronic medical records and claims, with unstructured clinical text and raw biological signals, including ECG waveforms, echocardiogram videos, radiology imaging, pulmonary function tests, and ultrasound, amounting to more than eight petabytes of deeply linked, multimodal patient data. The platform spans the full pharmaceutical development lifecycle through three core products: Precision Trial Designer, which uses real-world patient simulations to optimize clinical trial design; Evidence Explorer, which enables disease trajectory modeling, biomarker discovery, and real-world evidence generation; and Biomarker Developer, which validates AI algorithms against diverse real-world patient populations.
The platform’s impact is already measurable: in a trial emulation with a top-10 pharmaceutical company, Dandelion’s multimodal approach delivered projected cost savings of up to $84 million and accelerated timelines by up to 11 months compared to conventional trial design. Dandelion’s founding team includes Chief Science Officer Ziad Obermeyer, MD, a physician-scientist at Harvard Medical School and UC Berkeley; Sendhil Mullainathan, PhD, an economist at MIT and MacArthur Fellow; and Niyum Gandhi, Chief Financial and Strategy Officer of Mass General Brigham.
KEY QUOTES:
“Most clinical data is never seen, let alone used. ECGs, echocardiograms, radiology scans — these are generated millions of times a day, and they carry signals that no one is systematically capturing at scale. We built Dandelion to change that. This round lets us go deeper with our pharma partners and demonstrate what’s possible when the full richness of a patient’s clinical record is actually brought to bear on drug development.”
Elliott Green, CEO and Co-Founder, Dandelion Health
“Dandelion is doing something genuinely different in health data — combining the scale of a large real-world dataset with the depth of raw biological signals that most platforms simply cannot access. The team’s scientific depth and the partners they’ve drawn in make clear why pharma is turning to Dandelion to make smarter decisions across the drug development lifecycle.”
Aman Mahajan MD, PhD, Partner, Healthier Capital
